Skip to content

The Effects of Esketamine on Pulmonary Function and Early Clinical Outcomes in Elderly Patients Undergoing Joint Replacement Surgery

The Effects of Esketamine on Pulmonary Function and Early Clinical Outcomes in Elderly Patients Undergoing Joint Replacement Surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124135
Enrollment
Unknown
Registered
2026-05-07
Start date
2025-05-25
Completion date
Unknown
Last updated
2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip replacement surgery

Interventions

Esketamine Group:Anesthesia induction begins with a constant-rate pump infusion of esketamine (50 mg diluted to 50 ml) at a dose of 0.3 mg/kg, infused over 15 minutes
after the esketamine loading dose infusion is completed, it is switched to a continuous pump infusion at 0.3 mg/(kg·h).
Blank control group:Start the anesthesia induction by continuously pumping an equal amount of saline, with an infusion time of 15 minutes
after the loading dose is completed, switch to a continuous infusion of saline, with parameters consistent with those in group E.

Sponsors

Central Theater Command General Hospital of the Chinese People's Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 65–90 years, ASA classification II–III, BMI = 30 kg/m^2; 2. Patients undergoing hip replacement surgery under general anesthesia; 3. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Preoperative existing untreated lung diseases, including lung infections, moderate to severe chronic obstructive pulmonary disease (COPD, GOLD grade 2 or above, see Table 2.1), acute exacerbation, respiratory failure, ARDS, or pulmonary hypertension; 2. Preoperative low oxygen saturation (SpO2 < 90%) or concurrent systemic infection; 3. Untreated or poorly controlled hypertension or diabetes; 4. Presence of immune system diseases or long-term use of glucocorticoid medications; 5. Serious cardiovascular adverse events within 6 months before surgery, including angina, severe arrhythmia, myocardial infarction, as well as transient ischemic attack or stroke; 6. Severe liver or kidney dysfunction; 7. Cognitive impairment or mental illness; 8. Contraindications to esketamine use (such as pyloric obstruction, concurrent intracranial hypertension, increased intraocular pressure, untreated or inadequately treated hyperthyroidism, etc.)

Design outcomes

Primary

MeasureTime frame
FEV1% pred;Postoperative pulmonary complications;

Countries

China

Contacts

Public ContactLi Bixi

Chinese People's Liberation Army Central Theater Command General Hospital

lbxatghctc@163.com+86 153 2724 9768

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 16, 2026